GlassScriptPhysician profile
Cliff H Pruett
NPI 1104310234
$8,351.07
in general payments reported to CMS, 2019-2025
9 companies · $37.04 in 2025
The $37.04 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $349 · 2023: $1,029 · 2024: $6,936 · 2025: $37.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $7,044 · Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $7,044.12 |
| Food and Beverage | $957.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,959.40 | 2023-2024 | Amplatzer, Ensite |
| Boston Scientific Corporation | $643.99 | 2023 | Rotapro |
| E.R. Squibb & Sons, L.L.C. | $242.39 | 2022-2023 | Camzyos |
| Amgen INC. | $149.23 | 2024 | Repatha |
| Cardiovascular Systems INC. | $133.48 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $87.26 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $86.21 | 2022 | |
| Bridgebio Pharma, INC. | $37.04 | 2025 | Attruby |
| Merck Sharp & Dohme LLC | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cliff Pruett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.